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Abstract:
Objective: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma among adults and 
is characterized by heterogeneous clinical, immunophenotypic, and genetic features. Different mechanisms deregulating cell 
cycle and apoptosis play a role in the pathogenesis of DLBCL. Growth arrest DNA damage-inducible 45 (GADD45γ) is an 
important gene family involved in these mechanisms. The aims of this study are to determine the frequency of GADD45γ 
methylation, to evaluate the correlation between GADD45γ  methylation and protein expression, and to investigate the relation 
between methylation status and clinicopathologic parameters in DLBCL tissues and reactive lymphoid node tissues from 
patients with reactive lymphoid hyperplasia. 
Materials and Methods: Thirty-six tissue samples of DLBCL and 40 nonmalignant reactive lymphoid node tissues were 
analyzed in this study. Methylation-sensitive high-resolution melting analysis was used for the determination of GADD45γ 
methylation status. The GADD45γ protein expression was determined by immunohistochemistry.
Results: GADD45γ  methylation was frequent (50.0%) in DLBCL. It was also significantly higher in advanced-stage tumors 
compared with early-stage (p=0.041). In contrast, unmethylated GADD45γ  was associated with nodal involvement as the 
primary anatomical site (p=0.040). 
Conclusion: The results of this study show that, in contrast to solid tumors, the frequency of GADD45γ methylation is higher 
and this epigenetic alteration of GADD45γ  may be associated with progression in DLBCL. In addition, nodal involvement is 
more likely to be present in patients with unmethylated GADD45γ. 
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Introduction 
Diffuse large B-cell lymphoma (DLBCL) is the most 
common group of non-Hodgkin lymphomas (NHLs) and 
represents 30% to 40% of all newly diagnosed NHLs in Western 
countries. DLBCL represents a heterogeneous group of 
neoplasms with diversity in clinical presentation, morphology, 
and genetic and molecular properties [1]. It is well known 
that genetic and epigenetic changes that create a difference 
in gene expression profiles between normal and malign B 
cells are responsible for the heterogeneity of DLBCL. Genetic 
aberrations in DLBCL are chromosomal translocations, 
aberrant somatic hypermutations, and copy number variations 
including amplifications or deletions [2,3,4,5]. Other 
differences come from epigenetic modifications such as DNA 
methylation [6,7,8]. 
DNA methylation may lead to transcriptional silencing by 
at least 3 different mechanisms: inhibition of binding of the 
transcription factors to their specific sequences, a direct effect 
on nucleosome positioning, and recruitment of other nuclear 
factors that recognize the methylated CpG dinucleotide 
blocks binding other factors including transcription factors 
[9]. To date, a number of genes involved in the regulation 
of DNA repair, cell cycle control, and apoptosis, such as 
MGMT [10,11], DAPK1 [12], and GADD45γ [13], have been 
determined as hypermethylated in DLBCL. A recent study 
also showed that abnormal methylation patterns might be 
seen depending on chromosomal regions, gene density, and 
methylation status of neighboring genes in normal B-cell 
populations and NHL [8]. 
The growth arrest DNA damage-inducible (GADD45) gene 
family plays important roles in various cell functions such 
as DNA repair, cell-cycle control, and cell growth [14]. The 
members of the GADD45 gene family, GADD45γ, GADD45γ, 
and GADD45γ, are evolutionarily conserved and expressed 
in both fetal and adult tissues [15,16,17]. They act as stress 
sensors that modulate cellular response against various 
physical and environmental stress factors [14,17,18]. It is also 
suggested that GADD45 proteins may provide a link between 
DNA repair mechanisms and chromatin remodeling [19,20]. 
Although all 3 proteins have similar functions, these functions 
are not identical since they have different activation pathways 
depending on cell type and the source of the stress [17,21].
There are very limited data in the literature about the 
role of GADD45γ in DLBCL pathogenesis. In this study, 
we aimed to show the methylation status and expression 
profiles of GADD45γ in DLBCL tissues and nonmalignant 
reactive lymphoid node tissues (RLTs). We also focused on 
the relationship between GADD45γ methylation status and 
clinicopathologic parameters of DLBCL. 
Materials and Methods 
Tissue Samples
We analyzed 36 DLBCL tissue samples and 40 nonmalignant 
RLTs that were diagnosed in the Department of Pathology of 
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Öz:
Amaç: Diffüz büyük B-hücreli lenfoma (DBBHL) yetişkin bireylerde Hodgkin-dışı lenfomaların en yaygın tipidir ve klinik, 
immünofenotipik ve genetik özellikler açısından heterojen özellikler taşıması ile karakterizedir. DBBHL patogenezinde hücre 
döngüsü ve apoptoz regülasyonunu bozan farklı mekanizmalar rol oynamaktadır. Growth arrest DNA damage-inducible 45 
(GADD45γ), bu mekanizmalarda yer alan önemli bir gen ailesidir. Bu çalışmanın amaçları DBBHL doku örnekleri ve reaktif lenfoid 
hiperplazili bireylerin reaktif lenfoid doku örneklerinde GADD45γ  metilasyon sıklığını belirlemek, GADD45γ  metilasyonu 
ile protein ekspresyonu arasındaki ilişkiyi değerlendirmek ve DBBHL olgularında metilasyon durumunun klinikopatolojik 
parametrelerle ilişkisini araştırmaktır. 
Gereç ve Yöntemler: Bu çalışmada 36 adet DBBHL doku örnekleri ve 40 adet malign-olmayan reaktif lenfoid doku örnekleri 
analiz edildi. GADD45γ  metilasyon durumunu belirlemek için metilasyona-duyarlı yüksek çözünürlüklü erime eğrisi analizi 
kullanıldı. GADD45γ  protein ekspresyonu immünohistokimyasal analiz ile belirlendi.
Bulgular: DBBHL’de GADD45γ  metilasyonunun sık olduğu belirlendi (%50). Aynı zamanda, erken evre ile karşılaştırıldığında 
ileri evre tümörlerde GADD45γ  metilasyonu istatistiksel olarak anlamlı düzeyde yüksekti (p=0,041). Ancak, GADD45γ  metilasyon 
yokluğunun primer anatomik yerleşim olarak nodal tutulumla ilişkili olduğu belirlendi (p=0,040).
Sonuç: Bu çalışmanın sonuçları solid tümörlerin aksine, DBBHL’de GADD45γ  metilasyon sıklığının yüksek olduğunu ve 
GADD45γ  geninde gözlenen bu epigenetik değişimin, hastalığın progresyonu ile ilişkili olabileceğini göstermektedir. Buna ek 
olarak, nodal tutulum daha çok GADD45γ  metile olmayan olgularda gözlenmektedir.
Anahtar Sözcükler: GADD45γ, DNA metilasyonu, Diffüz büyük B-hücreli lenfoma
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Pamukkale University between 2009 and 2012. Tissue samples 
were collected from all patients before treatment. Based on 
Hans’s algorithm, DLBCL cases were classified as germinal 
center (GC) and non-GC in the Pathology Department 
[22]. All of the patients with DLBCL were also classified by 
Ann Arbor stage and International prognostic index (IPI) 
score according to the previously described criteria [23,24]. 
This study was approved by the Institutional Review Board 
of Pamukkale University and was in compliance with the 
Declaration of Helsinki.
Two consecutive sections of formalin-fixed and paraffin-
embedded (FFPE) tissues were used for DNA isolation 
and immunohistochemistry (IHC). DNA was isolated 
using a commercial kit according to the instructions of 
the manufacturer (QIAamp DNA Mini Kit, QIAGEN, the 
Netherlands) and IHC was performed using polyclonal 
antibody against GADD45γ as described previously [25].
Methylation-Sensitive High-Resolution Melting Analysis 
DNA samples underwent bisulfite treatment prior to 
methylation-sensitive high-resolution melting (MS-HRM) 
analysis by use of a commercial kit (EZ DNA Methylation-
Gold Kit, Zymo Research, USA). Forward and reverse primers 
were as follows, respectively: 5’-CGTCGTGTTGAGTTTTGGT 
and 5’-TAACCGCGAACTTCTTCCA [26]. The protocol for 
identification of the amplicon by MS-HRM analysis is given 
in Table 1. For the confirmation of melting temperature (Tm) 
degrees in MS-HRM analysis, commercially available control 
DNA samples were used (EpiTect Control DNA Set, QIAGEN). 
All analyses were performed on a LightCycler 480 instrument 
(Roche Diagnostics, Germany). 
Immunohistochemistry 
All immunostaining procedures including deparaffinization 
and antigen retrieval processes were performed automatically 
using the BenchMark XT automated stainer (Ventana Medical 
Systems, USA). GADD45γ (dilution: 1/200, Bioss Laboratories, 
USA) was used as the primary antibody. Larynx squamous cell 
carcinoma tissue samples were used as positive controls while 
negative controls were treated with the same IHC method by 
omitting the primary antibody. Granular cytoplasmic staining 
was assessed as positive. Immunohistochemical status of 
GADD45γ was scored as 0 (less than 25% positive cells), + 
(26% to 50% positive cells), ++ (51% to 75% positive cells), or 
+++ (more than 75% positive cells).
Statistical Analysis
The methylation status and protein expression level of 
GADD45γ between DLBCL patients and RLT controls was 
compared using the chi-square test. The Fisher’ exact test was 
used to compare the protein expression and methylation of 
GADD45γ. The age-adjusted frequency ratios of GADD45γ 
methylation were calculated using multiple logistic regression 
analysis. P<0.05 was considered to be statistically significant.
Results 
Clinicopathologic Parameters 
The median ages were 67.5 (range: 24-80) and 28.00 
(range: 1-79) years in DLBCL patients and RLT controls, 
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Table 1. High-resolution melting protocol for GADD45γ methylation.
Analysis Mode Cycle Target (°C) Hold Time Ramp Rate (°C/s) Acquisition Mode
Preincubation      
 1 95 10 min 4.4 -
Amplification      
  95 10 s 4.4 -
 50 60 15 s 2.2 -
  72 10 s 4.4 Single
High-resolution melting      
  95 1 min 4.4 -
  40 1 min 2.2 -
  65 1 s 1 -
  95 - 0.02 Continuous
Cooling      
 1 40 10 s - -
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respectively. The most frequent sites of extranodal involvement 
were as follows when the patients were classified according 
to the anatomic site of tumor: lung (6 cases, 42.9%), bone 
marrow (3 cases, 21.4%), liver (2 cases, 14.3%), and stomach 
(2 cases, 14.3%).
GADD45γ Methylation 
The Tm was 79±0.5 °C in the methylated region of the 
GADD45γ gene while the unmethylated region had a Tm of 
76±0.5 °C in MS-HRM analysis, which was also confirmed by 
the control DNA samples. According to this finding, GADD45γ 
methylation was present in 18 of the DLBCL patients (50%), 
whereas 16 (40%) of the controls were methylated (Table 2). 
Figure 1 shows the HRM analysis of GADD45γ methylation. 
No statistically significant difference was observed between 
DLBCL patients and controls in terms of GADD45γ methylation 
status (p=0.381). While the mean age was 48.56±22.69 
years in the group that had methylated GADD45γ, it was 
46.50±25.06 in the unmethylated group (p=0.716). Age status 
also did not significantly affect the methylation frequency 
of the GADD45γ gene (p=0.407). However, the methylation 
frequency in patients with advanced stage (stage 3 and 4) 
disease was 17 times higher than in early stages (stage 1 and 
2), which was statistically significant (p=0.041). In addition, 
there was a difference in the methylation status of GADD45γ 
between nodal and extranodal involvement (p=0.040). The 
frequency of GADD45γ methylation in the group with high 
clinical risk (IPI score 3-4) was 2.6 times higher than that in 
the low clinical risk group (IPI score 0-2); however, this was 
not statistically significant (p=0.298) (Table 2).
GADD45γ Protein Expression 
GADD45γ protein expression was observed to be (0) in 1, 
(+) in 18, (++) in 11, and (+++) in 6 of the DLBCL cases. In 
controls, the numbers were 8, 30, and 2 for (0), (+), and (++), 
respectively. None of the controls were (+++) for GADD45γ 
protein expression. Since the numbers of samples in the 
subgroups were small, samples were combined for ease of 
statistical analysis. While (0) and (+) were regarded as low 
protein expression, (++) and (+++) were accepted as high 
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Table 2. Associations of GADD45γ methylation and protein expression with clinicopathologic parameters in diffuse large 
B-cell lymphoma patients.
 
Clinicopathologic  
Parameters
GADD45γ Promoter 
Methylation
 GADD45γ Protein  
Expression
 
Absent Present p-value Low High p-value
Total patients 18 (50) 18 (50)  19 (52.8) 17 (47.2)  
Sex       
 Male 7 (50) 7 (50) 1.000 6 (42.9) 8 (57.1) 0.342
 Female 11 (50) 11 (50)  13 (59.1) 9 (40.9)  
Stage (Ann Arbor)       
 Early (I/II) 7 (87.5) 1 (12.5) 0.041 5 (62.5) 3 (37.5) 0.695
 Advanced (III/IV) 11 (39.3) 17 (60.7)  14 (50) 14 (50)  
Tumor location       
 Nodal 14 (63.6) 8 (36.4) 0.040 13 (59.1) 9 (40.9) 0.342
 Extranodal 4 (28.6) 10 (71.4)  6 (42.9) 8 (57.1)  
Cell origin       
  GC 9 (52.9) 8 (47.1) 0.738 11 (64.7) 6 (35.3) 0.175
  Non-GC 9 (47.4) 10 (52.6)  8 (42.1) 11 (57.9)  
IPI score       
  0-2 8 (61.5) 5 (38.5) 0.298 6 (46.2) 7 (53.8) 0.549
  3-5 10 (43.5) 13 (56.5)  13 (56.5) 10 (43.5)  
 
IPI: International prognostic index, GC: germinal center.
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protein expression (Figure 2). After this grouping, we found 
a statistically significant difference between DLBCL patients 
and controls (p<0.001) (Table 2). 
High-level expression of GADD45γ was present in 37.5% 
of early and 50% of advanced stage DLBCL patients. There 
was no significant relation between the protein expression 
level and the stage of DLBCL (p=0.695). Similarly, we did not 
find a significant association between the protein expression 
level and other clinicopathologic parameters (Table 2). 
Association of GADD45γ Methylation Status with 
GADD45γ Protein Expression
Among 18 DLBCL patients with methylated GADD45γ, 
we observed the high expression and the low expression of 
GADD45γ in 8 (44.4%) and 10 (55.6%) patients, respectively. 
The high expression of GADD45γ was determined in 9 
(50.0%) patients whose tumors had no methylated GADD45γ. 
Although we observed an association between GADD45γ 
methylation status and protein expression level in 48.7% of 
all patients included in this study, no significant correlation 
between the protein expression level and the status of 
methylation was observed (p=0.695) (Table 3).
Discussion 
As major stress sensors of cells, GADD45 proteins might be 
key players of cancer development and progression. Although 
several studies have focused on the relationship between 
GADD45γ gene expression and methylation in hematologic 
malignancies and solid tumors, there are limited data in the 
literature about the involvement of GADD45γ methylation and 
protein expression in DLBCL development [13,26,27]. To our 
knowledge, this is the first study investigating the association 
between the methylation and the level of protein expression of 
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Figure 1. The high-resolution melting curves for GADD45γ 
methylation in diffuse large B-cell lymphoma,  patients. 
a. Unmethylated GADD45γ DNA had a melting peak at 76±0.5 
°C, b. Methylated GADD45γ DNA had a melting peak at 79±0.5 
°C, c. Negative control (PCR-grade water was used instead of 
template DNA). 
Figure 2. Representative immunohistochemical detection of 
GADD45γ in diffuse large B-cell lymphoma (A-D). Diffuse large 
B-cell lymphoma comprising large neoplastic lymphoid cells 
with strong GADD45γ staining intensity (Score: +++) (A), with 
moderate GADD45γ staining intensity (Score: ++) (B), with 
weak GADD45γ staining intensity (Score: +) (C), and with no 
GADD45γ staining (Score: 0) (D) (original magnification 200x).
A
B
C
D
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GADD45γ in DLBCL patients and RLT controls. We detected 
GADD45γ methylation in 50.0% of DLBCL patients. MS-HRM 
used in this study was performed as previously described 
[26]. Zhang et al. found that the HRM protocol had high 
sensitivity, which allows the detection of low (1%) amounts 
of DNA methylation for GADD45γ [17]. It is well known that 
DNA derived from FFPE tissues is often degraded and the 
degradation of DNA is highly dependent on the sample age. 
In the present study, we used DNA samples extracted from 
FFPE tissues ranging in age from 2 to 5 years for MS-HRM. 
In a recent study, Kristensen et al. showed that DNA derived 
from up to 30-year-old FFPE tissue can be successfully used 
for DNA methylation analysis by MS-HRM [28]. Therefore, 
we suggest that MS-HRM analysis could be used to detect the 
methylation status of GADD45γ in FFPE tissue samples.
In non-small cell lung cancer, Na et al. reported that 
GADD45γ methylation was detected in 31.6% of cases. 
They also proposed that the silencing of GADD45γ by DNA 
methylation might be contributing to the development of 
lung cancer [29]. Bahar et al. detected GADD45γ methylation 
in 58% of human pituitary adenoma cases [27]. In 82% of 
patients whose tumors had no mRNA expression of GADD45γ, 
they detected promoter methylation by both methylation-
specific PCR and sodium bisulfite sequencing. Ying et al. 
reported the epigenetic inactivation of GADD45γ in primary 
samples from various cancer types and tumor cell lines 
[13]. In their study, they found that GADD45γ methylation 
was more frequent in leukemia and lymphomas (16%-88%) 
than solid tumors (11%-16%). In their series, 38% of primary 
DLBCL tissues had GADD45γ promoter methylation, which 
is concordant with our results. Our results and theirs may be 
showing the specificity of GADD45γ methylation according 
to the epithelial or mesenchymal origin of tumors. Another 
interesting finding of our study was the increasing frequency 
of GADD45γ methylation with tumor progression. We found 
a significantly higher GADD45γ methylation frequency in 
advanced stages than early stages. This may show that the loss 
of function in the GADD45γ tumor suppressor gene by DNA 
methylation plays a key role in the progression of DLBCL. 
It is well known that NHLs arise in different anatomical 
sites and they are considered as nodal and extranodal 
lymphomas according to the site [30,31]. The differences in 
clinical and biological characterizations between nodal and 
extranodal involvement are still not clear, as reflected in the 
heterogeneous nature of DLBCL in some sense, although 
there are a number of studies focused on the differences 
between lymphomas at different anatomical sites [32,33,34]. 
A recent study reported that primary extranodal involvement, 
especially at gastrointestinal, pulmonary, and liver/pancreatic 
sites, was associated with a worse outcome when compared 
to nodal involvement [35]. In our series, the majority of the 
patients had nodal involvement, while the remaining patients 
had both nodal and extranodal involvement. It was interesting 
that nodal involvement was observed in almost 80% of the 
patients with no methylated GADD45γ, with significant 
statistical difference, although there was no relation between 
the tissue involvement and IPI score. This finding may suggest 
that GADD45γ methylation status might be an important 
factor for the primary site of the lymphoma. Further studies 
are needed to identify the genetic and/or epigenetic differences 
between nodal and extranodal involvement in DLBCL. 
There is no consensus in the literature about the 
relationship between GADD45γ methylation status and 
protein expression levels. Ying et al. found no GADD45γ 
expression in the cell lines with GADD45γ methylation 
in their above mentioned study [13]. Bahar et al. found a 
significant correlation between GADD45γ methylation and 
low protein expression, although there was expression of 
GADD45γ transcript in 9% of the patients with GADD45γ 
methylation [27]. Furthermore, 18% of patients without 
GADD45γ methylation did not have GADD45γ expression, 
either. In the present study, we could not find an association 
between GADD45γ methylation and protein expression in 
51.3% of our cases. This finding may be explained by the 
following potential mechanisms: first, the method we used 
for the detection of methylation is not a quantitative method 
and those cases with GADD45γ expression might have low 
methylation levels that are not adequate for gene silencing. 
A number of studies have reported no significant association 
between protein expression and methylation status in 
different genes such as MGMT, DLC1, GATA4, NDK2, and 
RARRES1 [29,36]. It has also been reported that a gain of 
DNA methylation is not always associated with gene silencing. 
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Table 3. Association between GADD45γ methylation and its protein expression.
 
 
Methylated/High 
Expression
Methylated/Low 
Expression
Unmethylated/
High Expression
Unmethylated/
Low Expression
DLBCL patients 8 10 9 9
RLT controls 0 16 2 22
Total 8 26 11 31
DLBCL: Diffuse large B-cell lymphoma, RLT: reactive lymphoid node tissue.
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Kulis et al. characterized the DNA methylomes in patients 
with chronic lymphocytic leukemia and reported that there 
was a significant correlation between gene expression and 
DNA methylation levels in 4% of all CpGs [37]. In a study that 
identified DNA methylation differences in different human 
ethnic groups, it was shown that a gain of DNA methylation 
was associated with gene repression and activation in 63.0% 
and 37.0% of cases, respectively [38]. Second, our target in 
GADD45γ was relatively small because large amplicon sizes 
are generally unsuitable for HRM analysis. The GADD45γ 
gene has a unique CpG island that contains not only the 
promoter region but also exons [13,27]. Searching in the 
whole GADD45γ gene should be more accurate to detect the 
real methylation status. Third, since GADD45γ mutation was 
very rarely detected in primary tumors [13], the inhibition 
of expression might be due to other epigenetic mechanisms 
than DNA methylation, such as small noncoding RNAs and 
histone modifications. Finally, the polyclonal antibody that we 
used for IHC due to unavailability of commercial monoclonal 
antibody against GADD45γ protein might have cross-reacted 
with other epitopes in colocalized protein targets [39].
In summary, we found that the frequency of GADD45γ 
methylation in DLBCL was higher than that reported in solid 
tumors. We also observed that the frequency of GADD45γ 
methylation in advanced stages was significantly higher than 
that in early stages. In comparison to nodal DLBCL, GADD45γ 
was commonly methylated in extranodal DLBCL. These 
findings indicated that the silencing of GADD45γ by DNA 
methylation may play a role in the progression and the tissue 
involvement of DLBCL. Further studies are needed to evaluate 
the role of other members of the GADD45 family and their 
partners in DLBCL.
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